{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:44:37Z","timestamp":1794451477115,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>\n                        <jats:bold>Abstract<\/jats:bold>\n                     <\/jats:title><jats:p>COVID-19 caused by SARS-CoV-2 has continually been serious threat to public health worldwide. While a few anti-SARS-CoV-2 therapeutics are currently available, their antiviral potency is not sufficient. Here, we identify two orally available 4-fluoro-benzothiazole-containing small molecules, TKB245 and TKB248, which specifically inhibit the enzymatic activity of main protease (M<jats:sup>pro<\/jats:sup>) of SARS-CoV-2 and significantly more potently block the infectivity and replication of various SARS-CoV-2 strains than nirmatrelvir, molnupiravir, and ensitrelvir in cell-based assays employing various target cells. Both compounds also block the replication of Delta and Omicron variants in human-ACE2-knocked-in mice. Native mass spectrometric analysis reveals that both compounds bind to dimer M<jats:sup>pro<\/jats:sup>, apparently promoting M<jats:sup>pro<\/jats:sup> dimerization. X-ray crystallographic analysis shows that both compounds bind to M<jats:sup>pro<\/jats:sup>\u2019s active-site cavity, forming a covalent bond with the catalytic amino acid Cys-145 with the 4-fluorine of the benzothiazole moiety pointed to solvent. The data suggest that TKB245 and TKB248 might serve as potential therapeutics for COVID-19 and shed light upon further optimization to develop more potent and safer anti-SARS-CoV-2 therapeutics.<\/jats:p>","DOI":"10.1038\/s41467-023-36729-0","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T05:02:39Z","timestamp":1677301359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Identification of SARS-CoV-2 Mpro inhibitors containing P1\u2019 4-fluorobenzothiazole moiety highly active against SARS-CoV-2"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-3532","authenticated-orcid":false,"given":"Nobuyo","family":"Higashi-Kuwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-8793","authenticated-orcid":false,"given":"Kohei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-0040","authenticated-orcid":false,"given":"Hironori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0262-6296","authenticated-orcid":false,"given":"Haydar","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-911X","authenticated-orcid":false,"given":"Hiromi","family":"Ogata-Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-6191","authenticated-orcid":false,"given":"Takahiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-2608","authenticated-orcid":false,"given":"Takuya","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-240X","authenticated-orcid":false,"given":"Nobutoki","family":"Takamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9401-8118","authenticated-orcid":false,"given":"Naoki","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-3397","authenticated-orcid":false,"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-5888","authenticated-orcid":false,"given":"Debananda","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-3395","authenticated-orcid":false,"given":"Yosuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-831X","authenticated-orcid":false,"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-1624","authenticated-orcid":false,"given":"Kazuya","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-0180","authenticated-orcid":false,"given":"Satoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-4248","authenticated-orcid":false,"given":"Akie","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-1347","authenticated-orcid":false,"given":"Junji","family":"Saruwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-3993","authenticated-orcid":false,"given":"Yukiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Sukenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-1576","authenticated-orcid":false,"given":"Yuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-6653","authenticated-orcid":false,"given":"Kiyoto","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-9031","authenticated-orcid":false,"given":"Shun","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-9542","authenticated-orcid":false,"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-1561","authenticated-orcid":false,"given":"Tadashi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-4720","authenticated-orcid":false,"given":"Shogo","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-2579","authenticated-orcid":false,"given":"Hirokazu","family":"Tamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9274-3853","authenticated-orcid":false,"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"36729_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"36729_CR2","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41591-021-01616-y","volume":"27","author":"MD Van Kerkhove","year":"2021","unstructured":"Van Kerkhove, M. D. COVID-19 in 2022: controlling the pandemic is within our grasp. Nat. Med. 27, 2070 (2021).","journal-title":"Nat. Med."},{"key":"36729_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.35772\/ghm.2020.01111","volume":"2","author":"H Mitsuya","year":"2020","unstructured":"Mitsuya, H. Fight against COVID-19 but avoid disruption of services for other communicable diseases (CDs) and noncommunicable diseases (NCDs). Glob. Health Med 2, 343\u2013345 (2020).","journal-title":"Glob. Health Med"},{"key":"36729_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. C4591001 Clinical Trial Group. Safety And Efficacy Of The Bnt162b2 Mrna Covid-19 Vaccine. N. Engl. J. Med 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"36729_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","volume":"49","author":"S Khare","year":"2021","unstructured":"Khare, S. et al. Curation Team GC, Maurer-Stroh S. GISAID\u2019s role in pandemic response. China CDC Wkly 49, 1049\u20131051 (2021).","journal-title":"China CDC Wkly"},{"key":"36729_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35772\/ghm.2021.01010","volume":"3","author":"DD Richman","year":"2021","unstructured":"Richman, D. D. COVID-19 vaccines: implementation, limitations and opportunities. Glob. Health Med 3, 1\u20135 (2021).","journal-title":"Glob. Health Med"},{"key":"36729_CR7","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"GR Painter","year":"2019","unstructured":"Painter, G. R. et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antivir. Res 171, 104597 (2019).","journal-title":"Antivir. Res"},{"key":"36729_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"36729_CR9","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/cid\/ciac512","volume":"76","author":"J Boucau","year":"2022","unstructured":"Boucau, J. et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin. Infect. Dis. 76, e526\u2013e529 (2022). ciac512.","journal-title":"Clin. Infect. Dis."},{"key":"36729_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"36729_CR11","doi-asserted-by":"publisher","unstructured":"Yanmei Hu, Eric M. et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. Preprint at https:\/\/doi.org\/10.1101\/2022.06.28.497978 (2022).","DOI":"10.1101\/2022.06.28.497978"},{"key":"36729_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1054-3589(07)56006-0","volume":"56","author":"H Mitsuya","year":"2008","unstructured":"Mitsuya, H., Maeda, K., Das, D. & Ghosh, A. K. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv. Pharm. 56, 169\u2013197 (2008).","journal-title":"Adv. Pharm."},{"key":"36729_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"36729_CR14","doi-asserted-by":"publisher","first-page":"e01833","DOI":"10.1128\/mBio.01833-20","volume":"11","author":"SI Hattori","year":"2020","unstructured":"Hattori, S. I. et al. GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection. mBio 11, e01833\u201320 (2020).","journal-title":"mBio"},{"key":"36729_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20900-6","volume":"12","author":"SI Hattori","year":"2021","unstructured":"Hattori, S. I. et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 12, 668 (2021).","journal-title":"Nat. Commun."},{"key":"36729_CR16","doi-asserted-by":"publisher","first-page":"e0349022","DOI":"10.1128\/spectrum.03490-22","volume":"10","author":"N Higashi-Kuwata","year":"2022","unstructured":"Higashi-Kuwata, N. et al. Generation of angiotensin-converting enzyme 2\/transmembrane protease serine 2-double-positive human induced pluripotent stem cell-derived spheroids for anti-severe acute respiratory syndrome coronavirus 2 drug evaluation. Microbiol Spectr. 10, e0349022 (2022).","journal-title":"Microbiol Spectr."},{"key":"36729_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"36729_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","volume":"68","author":"P Thanigaimalai","year":"2013","unstructured":"Thanigaimalai, P. et al. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur. J. Med Chem. 68, 372\u2013384 (2013).","journal-title":"Eur. J. Med Chem."},{"key":"36729_CR19","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1021\/acs.jmedchem.1c00665","volume":"65","author":"S Konno","year":"2022","unstructured":"Konno, S. et al. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. J. Med Chem. 65, 2926\u20132939 (2022).","journal-title":"J. Med Chem."},{"key":"36729_CR20","doi-asserted-by":"publisher","first-page":"9426","DOI":"10.1073\/pnas.87.23.9426","volume":"87","author":"T Shirasaka","year":"1990","unstructured":"Shirasaka, T. et al. Lipophilic halogenated congeners of 2\u2019,3\u2019-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl Acad. Sci. USA 87, 9426\u20139430 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36729_CR21","doi-asserted-by":"publisher","first-page":"e28020","DOI":"10.7554\/eLife.28020","volume":"6","author":"M Aoki","year":"2017","unstructured":"Aoki, M. et al. A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. Elife 6, e28020 (2017).","journal-title":"Elife"},{"key":"36729_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65993-z","volume":"10","author":"H Bulut","year":"2020","unstructured":"Bulut, H. et al. Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Sci. Rep. 10, 10664 (2020).","journal-title":"Sci. Rep."},{"key":"36729_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ejmech.2017.11.055","volume":"143","author":"T Naret","year":"2018","unstructured":"Naret, T. et al. A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: Design, synthesis, molecular modelling, and biological evaluation. Eur. J. Med Chem. 143, 473\u2013490 (2018).","journal-title":"Eur. J. Med Chem."},{"key":"36729_CR24","doi-asserted-by":"publisher","first-page":"10633","DOI":"10.1021\/acsomega.0c00830","volume":"5","author":"M Inoue","year":"2020","unstructured":"Inoue, M., Sumii, Y. & Shibata, N. Contribution of organofluorine compounds to pharmaceuticals. ACS Omega 5, 10633\u201310640 (2020).","journal-title":"ACS Omega"},{"key":"36729_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","volume":"607","author":"R Uraki","year":"2022","unstructured":"Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119\u2013127 (2022).","journal-title":"Nature"},{"key":"36729_CR26","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1172\/JCI116463","volume":"91","author":"WY Gao","year":"1993","unstructured":"Gao, W. Y., Shirasaka, T., Johns, D. G., Broder, S. & Mitsuya, H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest 91, 2326\u20132333 (1993).","journal-title":"J. Clin. Invest"},{"key":"36729_CR27","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F. & Matsuyama, S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 86, 6537\u20136545 (2012).","journal-title":"J. Virol."},{"key":"36729_CR28","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med Chem."},{"key":"36729_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jhep.2020.12.006","volume":"74","author":"N Higashi-Kuwata","year":"2021","unstructured":"Higashi-Kuwata, N. et al. Identification of a novel long-acting 4\u2019-modified nucleoside reverse transcriptase inhibitor against HBV. J. Hepatol. 74, 1075\u20131086 (2021).","journal-title":"J. Hepatol."},{"key":"36729_CR30","doi-asserted-by":"publisher","first-page":"22741","DOI":"10.1074\/jbc.M502556200","volume":"280","author":"WC Hsu","year":"2005","unstructured":"Hsu, W. C. et al. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J. Biol. Chem. 280, 22741\u201322748 (2005).","journal-title":"J. Biol. Chem."},{"key":"36729_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/jb\/mvm246","volume":"143","author":"S Chen","year":"2008","unstructured":"Chen, S. et al. Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis. J. Biochem 143, 525\u2013536 (2008).","journal-title":"J. Biochem"},{"key":"36729_CR32","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/cid\/ciac512","volume":"76","author":"J Boucau","year":"2022","unstructured":"Boucau, J. et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin. Infect. Dis. 76, e526\u2013e529 (2022). ciac512.","journal-title":"Clin. Infect. Dis."},{"key":"36729_CR33","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/AAC.00277-07","volume":"51","author":"H Nakata","year":"2007","unstructured":"Nakata, H. et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4\u2019-ethynyl-2-fluoro-2\u2019-deoxyadenosine. Antimicrob. Agents Chemother. 51, 2701\u20132708 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"36729_CR34","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36729_CR35","doi-asserted-by":"publisher","first-page":"e0155121","DOI":"10.1128\/jvi.01551-21","volume":"96","author":"Y Takamatsu","year":"2022","unstructured":"Takamatsu, Y. et al. Highly neutralizing COVID-19 convalescent plasmas potently block sars-cov-2 replication and pneumonia in syrian hamsters. J. Virol. 96, e0155121 (2022).","journal-title":"J. Virol."},{"key":"36729_CR36","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1073\/pnas.1400027111","volume":"111","author":"H Hayashi","year":"2014","unstructured":"Hayashi, H. et al. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc. Natl Acad. Sci. USA 111, 12234\u201312239 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36729_CR37","doi-asserted-by":"publisher","first-page":"105365","DOI":"10.1016\/j.isci.2022.105365","volume":"25","author":"K Tsuji","year":"2022","unstructured":"Tsuji, K. et al. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience 25, 105365 (2022).","journal-title":"iScience"},{"key":"36729_CR38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","volume":"18","author":"S Alseekh","year":"2021","unstructured":"Alseekh, S. et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat. Methods 18, 747\u2013756 (2021).","journal-title":"Nat. Methods"},{"key":"36729_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1107\/S2059798317017235","volume":"74","author":"G Winter","year":"2018","unstructured":"Winter, G. et al. DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D. Struct. Biol. 74, 85\u201397 (2018).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"36729_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1107\/S0907444909042589","volume":"66","author":"A Vagin","year":"2010","unstructured":"Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr D. Biol. Crystallogr 66, 22\u201325 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"36729_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D. Biol. Crystallogr 67, 355\u2013367 (2011).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"36729_CR42","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","unstructured":"Sch\u00fcttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D. Biol. Crystallogr 60, 1355\u20131363 (2004).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"36729_CR43","unstructured":"Schr\u00f6dinger, L. & DeLano, W., PyMOL, Available at: http:\/\/www.pymol.org\/pymol. (2020)."},{"key":"36729_CR44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera \u2013 a visualization system for exploratory research and analysis. J. Comput Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36729-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T06:03:45Z","timestamp":1677305025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36729-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36729"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36729-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1076"}}